Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.
Weinstock-Guttman B, et al. Among authors: hotermans c.
J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19.
J Neurol. 2012.
PMID: 22008873
Clinical Trial.